Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 12, 2016 - Issue 4
Submit an article Journal homepage
568
Views
4
CrossRef citations to date
0
Altmetric
Research Papers

Tolerability of 2 doses of pandemic influenza vaccine (Focetria®) and of a prior dose of seasonal 2009-2010 influenza vaccination in the Netherlands

N. A. T. van der MaasCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the NetherlandsCorrespondence[email protected]
,
S. GodefrooijCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands;Department of Health Science, VU University Amsterdam, Amsterdam, the Netherlands
,
P. E. Vermeer-de BondtCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
,
H. E. de MelkerCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
&
J. KemmerenCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
Pages 1027-1032 | Received 02 Sep 2015, Accepted 10 Nov 2015, Published online: 22 Mar 2016

References

  • Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 1999; 17 Suppl 1:S3–10; PMID:10471173; http://dx.doi.org/10.1016/S0264-410X(99)00099-7
  • Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, et al. Assessment of the immunogenicity and safety of varying doses of an MF59(R)-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. Vaccine 2012; 30:5030–7; PMID:22472791; http://dx.doi.org/10.1016/j.vaccine.2012.03.053
  • Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1–62; PMID:20689501
  • Gasparini R, Lai P, Panatto D. Today's influenza vaccines-why an adjuvant is needed and how it works. European Infectious Disease 2010; 4:36–40
  • WHO. Influenza vaccines-WHO position paper. 2005
  • Stein ML, Van Vliet H, Timen A. Chronological overview of the 2009 H1N1 pandemic and the response of the Centre for Infectious Disease Control (Cib) of the National Institute for Public Health and the Environment (RIVM). Bilthoven: National Institute for Public Health and the Environment, 2010.
  • van Puijenbroek EP, van Grootheest AC. Monitoring adverse events of vaccines against Mexican flu. Int J Risk Saf Med 2011; 23:81–7; PMID:21673415
  • Harmark L, van Hunsel F, Hak E, van Grootheest K. Monitoring the safety of influenza A (H1N1) vaccine using web-based intensive monitoring. Vaccine 2011; 29:1941–7; PMID:21236235; http://dx.doi.org/10.1016/j.vaccine.2010.12.123
  • Tacken M, Mulder J, Visscher S, Tiersma W, Donkers J, Verheij R, et al. Monitoring vaccinatiegraad Nationaal Programma Grieppreventie 2009. Nijmegen: LINH, 2010
  • Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, Pellegrini M, Veitch K, Gaitatzis N. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract 2010; 64:432–8; PMID:20039974; http://dx.doi.org/10.1111/j.1742-1241.2009.02309.x
  • Schoffelen T, Wong A, Rumke HC, Netea MG, Timen A, van Deuren M, Vermeer-de Bondt PE. Adverse events and association with age, sex and immunological parameters of Q fever vaccination in patients at risk for chronic Q fever in the Netherlands 2011. Vaccine 2014; 32:6622–30; PMID:25446824; http://dx.doi.org/10.1016/j.vaccine.2014.09.061
  • McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol 2009; 21:418–24; PMID:19570667; http://dx.doi.org/10.1016/j.coi.2009.05.023
  • Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009; 27:6959–65; PMID:19751689; http://dx.doi.org/10.1016/j.vaccine.2009.08.101
  • Simonsen L, Viboud C, Taylor RJ, Miller MA, Jackson L. Influenza vaccination and mortality benefits: new insights, new opportunities. Vaccine 2009; 27:6300–4; PMID:19840664; http://dx.doi.org/10.1016/j.vaccine.2009.07.008

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.